Overview

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study is for subjects with a type of skin cancer called melanoma. The main purpose of this study is to examine the safety of the study drug (Poly-ICLC) in patients with your disease. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for your disease.
Phase:
Phase 1
Details
Lead Sponsor:
Medical University of South Carolina
Treatments:
Carboxymethylcellulose Sodium
Poly I-C
Poly ICLC